Xiangxue Pharmaceutical Purchases FlexFactory from GE Healthcare

Officials at GE Healthcare say the company will provide China-based Xiangxue Pharmaceutical (XPH) with a FlexFactory™ for cell therapy. The system, expected to be operational in March 2019, is a semiautomated end-to-end manufacturing platform to help scale up, digitize, and accelerate manufacturing processes for cell therapy clinical trials and future commercialization.According to GE Healthcare, this project marks the first application of FlexFactory for cell immunotherapy drugs based on